{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:32:57Z","timestamp":1788993177327,"version":"build-2803163510"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Assess cognitive effects of adjunctive perampanel in adolescents.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this double\u2010blind study (ClinicalTrials.gov identifier:<jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>01161524), patients aged 12 to &lt;18 years with partial\u2010onset seizures despite receiving 1\u20133 antiepileptic drugs were randomized (2:1) to perampanel or placebo. Perampanel was increased weekly in 2\u2010mg increments to 8\u201312 mg\/day (6\u2010week titration; 13\u2010week maintenance). Changes in neuropsychological outcomes were assessed at end of maintenance: Cognitive Drug Research (<jats:styled-content style=\"fixed-case\">CDR<\/jats:styled-content>) System Global Cognition Score (primary end point), five<jats:styled-content style=\"fixed-case\">CDR<\/jats:styled-content>System domain T\u2010scores (secondary end points), letter fluency, category fluency, and Lafayette Grooved Pegboard Test (<jats:styled-content style=\"fixed-case\">LGPT<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred thirty\u2010three patients were randomized. In the full analysis set, there were no differences of perampanel (n = 79) vs. placebo (n = 44) in<jats:styled-content style=\"fixed-case\">CDR<\/jats:styled-content>System Global Cognition Score (least squares mean change, \u22120.6 vs. 1.6; p = 0.145), Quality of Working Memory (1.1 vs. 2.0; p = 0.579), or Power of Attention (\u22126.9 vs. \u22122.7; p = 0.219). There were small differences with perampanel vs. placebo in other<jats:styled-content style=\"fixed-case\">CDR<\/jats:styled-content>System domains: improvements in Quality of Episodic Memory (3.0 vs. \u22121.2; p = 0.012), and worsening in Continuity of Attention (\u22123.3 vs. 1.6; p = 0.013) and Speed of Memory (0.3 vs. 7.0; p = 0.032). Letter fluency, category fluency, and<jats:styled-content style=\"fixed-case\">LGPT<\/jats:styled-content>were not significantly different between groups. The most frequent adverse events with perampanel were dizziness (30.6%) and somnolence (15.3%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Significance<\/jats:title><jats:p>Perampanel did not differ from placebo in the global cognitive score, two of five subdomains, and four other cognitive measures. Perampanel was worse on two and better on one subdomain.<\/jats:p><\/jats:sec>","DOI":"10.1111\/epi.13279","type":"journal-article","created":{"date-parts":[[2016,1,2]],"date-time":"2016-01-02T15:23:48Z","timestamp":1451748228000},"page":"243-251","source":"Crossref","is-referenced-by-count":96,"title":["Cognitive effects of adjunctive perampanel for partial\u2010onset seizures: A randomized trial"],"prefix":"10.1111","volume":"57","author":[{"given":"Kimford J.","family":"Meador","sequence":"first","affiliation":[{"name":"Department of Neurology and Neurological Sciences Stanford University School of Medicine Stanford California U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichen","family":"Yang","sequence":"additional","affiliation":[{"name":"Eisai Neuroscience and General Medicine PCU Eisai Inc. Woodcliff Lake New Jersey U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus Eric","family":"Pi\u00f1a\u2010Garza","sequence":"additional","affiliation":[{"name":"The Children's Hospital at TriStar Centennial Nashville Tennessee U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Laurenza","sequence":"additional","affiliation":[{"name":"Eisai Neuroscience and General Medicine PCU Eisai Inc. Woodcliff Lake New Jersey U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Eisai Neuroscience and General Medicine PCU Eisai Inc. Woodcliff Lake New Jersey U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Wesnes","sequence":"additional","affiliation":[{"name":"Wesnes Cognition Streatley on Thames United Kingdom"},{"name":"Psychology Department Northumbria University Newcastle United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,1]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"682","article-title":"Epilepsy and neuropsychological comorbidities","volume":"19","author":"Rudzinski LA","year":"2013","journal-title":"Continuum"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00894.x"},{"key":"e_1_2_8_4_1","first-page":"989","volume-title":"Wyllie's treatment of epilepsy: principles & practice","author":"Meador KJ","year":"2014"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2000.2.3\/kwesnes"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.10.1195"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1067\/mtc.2001.114099"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03399-7"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.appet.2006.06.009"},{"key":"e_1_2_8_10_1","first-page":"34","article-title":"Coherence training in children with attention\u2010deficit hyperactivity disorder: cognitive functions and behavioral changes","volume":"16","author":"Lloyd A","year":"2010","journal-title":"Altern Ther Health Med"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1138741600004066"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/bem.20128"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.appet.2011.09.004"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.appet.2003.08.009"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.appet.2012.08.008"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(13)70958-1"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2008.11.012"},{"issue":"1","key":"e_1_2_8_18_1","first-page":"20","article-title":"Absence of a sertraline\u2010mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine","volume":"57","author":"Rapeport WG","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_8_19_1","first-page":"A41","article-title":"Remacemide does not affect cognitive function following multiple dosing","volume":"12","author":"Lockton JA","year":"1998","journal-title":"J Psychopharmacol"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03109.x"},{"key":"e_1_2_8_21_1","unstructured":"European Medicines Agency.Fycompa summary of product characteristics Available at:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002434\/WC500130815.pdf. Accessed November 30 2015."},{"key":"e_1_2_8_22_1","unstructured":"Food and Drug Administration.Fycompa Prescribing Information 2015. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202834lbl.pdf. Accessed November 30 2015."},{"key":"e_1_2_8_23_1","volume-title":"Kaufman Brief Intelligence Test","author":"Kaufman AS","year":"2004"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(02)00236-3"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130000533"},{"key":"e_1_2_8_27_1","volume-title":"Neuropsychological assessment","author":"Lezak MD","year":"2012"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00194333"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00131.x"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000232737.72555.06"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1754.2003.00180.x"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02197.x"},{"key":"e_1_2_8_33_1","doi-asserted-by":"crossref","first-page":"P3.271","DOI":"10.1212\/WNL.82.10_supplement.P3.271","article-title":"Interim efficacy and safety analysis of adjunctive perampanel in the adolescent population from the extension phase of 3 double\u2010blind, placebo\u2010controlled, phase 3 (core) studies in patients with refractory partial\u2010onset seizures","volume":"82","author":"Renfroe B","year":"2014","journal-title":"Neurology"},{"key":"e_1_2_8_34_1","unstructured":"RosenfeldW RozentalsG YangH et al.Efficacy and safety of adjunctive perampanel in the subgroup of adolescent patients with refractory partial onset seizures included in the 3 double\u2010blind placebo\u2010controlled Phase III clinical trials. Poster E\u201018 presented at the 41st Annual Meeting of the Child Neurology Society 2012."},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2015.02.008"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.8_suppl_5.S9"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fepi.13279","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.13279","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/epi.13279","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.13279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T15:09:57Z","timestamp":1718291397000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.13279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1111\/epi.13279"],"URL":"https:\/\/doi.org\/10.1111\/epi.13279","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}